Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Rheumatology (Oxford) ; 63(3): 787-790, 2024 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-37540112

RESUMEN

OBJECTIVE: Monoclonal gammopathy of undetermined significance (MGUS) is common, but there are scarce data regarding the effect of DMARDs on this premalignant condition. We aimed to evaluate the impact of JAK inhibitors (JAKis) on MGUS when initiated for an active rheumatic disease. METHODS: Patients with monoclonal abnormality prior to JAKi initiation for an active rheumatic disease were identified through the MAJIK-SFR Registry, a French multicentre prospective study. Clinical and biological data were collected using a standardized case report form. RESULTS: Twenty patients were identified with a mean age of 65 years and a diagnosis of RA (n = 15), PsA (n = 3), and axial SpA (n = 2). The JAKi prescribed was baricitinib (n = 9), tofacitinib (n = 6) or upadacitinib (n = 5), with a mean duration of 15.5 months. Seventeen patients had individualized serum monoclonal protein (IgG kappa n = 9; IgG lambda n = 4; IgM kappa n = 3; IgA lambda n = 1) ranging from 0.16 to 2.3 g/dl, and three patients did not have an initial measurable spike but they had a positive serum immunofixation. With a follow-up of 4-28 months, the serum monoclonal protein level decreased in 8 of 17 patients (47%), remained stable in 8 patients (47%) and increased in 1 patient (6%). The maximal decrease observed was an initial IgG kappa of 2.3 g/dl, decreasing to 0.2 g/dl at month 14. CONCLUSION: This study provides reassuring and promising data on MGUS evolution in patients treated with JAKis for rheumatic diseases, which may guide the choice of treatment in patients with both conditions.


Asunto(s)
Artritis Psoriásica , Inhibidores de las Cinasas Janus , Gammopatía Monoclonal de Relevancia Indeterminada , Enfermedades Reumáticas , Humanos , Anciano , Gammopatía Monoclonal de Relevancia Indeterminada/tratamiento farmacológico , Inhibidores de las Cinasas Janus/uso terapéutico , Estudios Prospectivos , Anticuerpos Monoclonales , Enfermedades Reumáticas/tratamiento farmacológico , Inmunoglobulina G
3.
Rev Med Interne ; 41(9): 622-627, 2020 Sep.
Artículo en Francés | MEDLINE | ID: mdl-32660858

RESUMEN

INTRODUCTION: Cocaine use is associated with multiple complications, some of which can mimic systemic diseases, especially Antineutrophil Cytoplasmic Antibody (ANCA) associated vasculitis. We report a case of Cocaine Induced Midline Destructive Lesions (CIMDL) for which a diagnosis of granulomatosis with polyangiitis (GPA) was discussed. CASE REPORT: A 42-year-old male, cocaine consumer, was admitted in our department for a centrofacial destructive process. He had no extra ear, nose and throat (ENT) involvement. ANCA were positive with a perinuclear fluorescence pattern and an anti-Proteinase 3 specificity. Regarding this unusual immunologic pattern and in the absence of histological argument for a GPA, a diagnosis of CIMDL was made. CONCLUSION: CIMDL is a centrofacial destructive process due to intranasal cocaine use. It is frequently associated with the presence of p-ANCA with both anti-HNE and anti-PR3 specificity.


Asunto(s)
Trastornos Relacionados con Cocaína/complicaciones , Granulomatosis con Poliangitis/etiología , Perforación del Tabique Nasal/etiología , Adulto , Anticuerpos Anticitoplasma de Neutrófilos/efectos adversos , Anticuerpos Anticitoplasma de Neutrófilos/sangre , Trastornos Relacionados con Cocaína/diagnóstico , Diagnóstico Diferencial , Granuloma Letal de la Línea Media/diagnóstico , Granuloma Letal de la Línea Media/etiología , Granulomatosis con Poliangitis/diagnóstico , Humanos , Masculino , Perforación del Tabique Nasal/diagnóstico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...